The possible number of chiral and achiral tetrasubstituted [2.2]paracyclophanes possessing different types of symmetry (C(2), C(i), C(s), C(2v), C(2h)) is evaluated and a unified independent trivial naming descriptor system is introduced. The reactivity and regioselectivity of the electrophilic substitution of the chiral pseudo-meta- and achiral pseudo-para-disubstituted [2.2]paracyclophanes are investigated in an approach suggested to be general for the synthesis of bis-bifunctional [2.2]paracyclophanes. The mono- and diacylation of chiral pseudo-meta-dihydroxy[2.2]paracyclophane 14 with acetylchloride occur ortho-regioselectively to produce tri- 22, 23 and symmetrically 21 tetrasubstituted acyl derivatives. The same reaction with benzoylchloride is neither regio-, nor chemoselective, and gives rise to a mixture of ortho-/para-, mono-/diacylated compounds 27-31. The double acylation of pseudo-meta-dimethoxy[2.2]paracyclophane 18 is completely para-regioselective. Electrophilic substitution of pseudo-meta-bis(methoxycarbonyl)[2.2]paracyclophane 20 regioselectively generates the pseudo-gem-substitution pattern. Formylation of this substrate produces the monocarbonyl derivatives 35 only, whereas the Fe-catalyzed bromination may be directed towards mono- 36 or disubstitution 37 products chemoselectively by varying the reactions conditions. The diacylation and dibromination reactions of the respective achiral diphenol 12 and bis(methoxycarbonyl) 40 derivatives of the pseudo-para-structure retain regioselectivities which are characteristic for their pseudo-meta-regioisomers. Imino ligands 26, 25, and 39, which were obtained from monoacyl- 22 and diacyldihydroxy[2.2]paracyclophanes 21, 38, are tested as chiral ligands in stereoselective Et(2)Zn addition to benzaldehyde producing 1-phenylpropanol with ee values up to 76 %.
Two useful approaches to ortho-acylhydroxy[2.2]paracyclophanes, starting from 4-hydroxy[2.2]paracyclophane, have been developed. TiCl 4 -catalyzed Fries rearrangement and direct acylation occur regioselectively (to the ortho position with respect to the hydroxy group), leading to 4-acetyl-5-hydroxy[2.2]paracyclophane (3) and 4-benzoyl-5-hydroxy[2.2]-[a] A. N. Nesmeyanov Institute of Organoelement Compounds, 3295 paracyclophane (4) in high to excellent chemical yields. For compound 4, an X-ray investigation has been performed. ortho-Acylhydroxy[2.2]paracyclophanes 3 and 4 have been obtained in enantiomerically enriched forms (ee 92−99%) and the absolute configurations of their enantiomers have been determined. parative routes to enantiomerically enriched ortho-acylhydroxy[2.2]paracyclophanes were elaborated.
nitriles nitriles (benzene compounds) Q 0520
-125Asymmetric Trimethylsilylcyanation of Benzaldehyde Catalyzed by (Salen)Ti(IV) Complexes Derived from (R)-and/or (S)-4-Hydroxy-5-formyl[2.2]paracyclophane and Diamines.-A method for the catalytic, asymmetric preparation of cyanohydrins, versatile intermediates in organic synthesis, is presented using enantiomerically pure, cyclophane-based (salen)Ti(IV) complexes as catalysts. -(BELOKON, Y.; MOSCALENKO, M.; IKONNIKOV, N.; YASHKINA, L.; ANTONOV, D.; VORONTSOV, E.; ROZENBERG, V.; Tetrahedron
903-919.[13] The simulations for 1 were performed according to the published procedure [12] with a temperature parameter of 303 K and 2 x lo6 macro steps. Maximum step lengths were 20" ($), 20" ($). 25' (w), and 2.5" (T = C1'-01'-C6), leading to an overall acceptance ratio of 0.48. Five minima could be identified:minimum A, E,., = 0.00 kcalmol-'); r#J = 49", $ =124'. m = -80" (minimum B, E,., = 0.20 kcalmol-I); = 55", $ =149". 0) = -61" (minimum C, E,,, = 0.56 kcalmol-I), $ = 55'. $ = -122'. (I) = -65" (minimum D, EcG, =1.90 kcalmol-I); r#J = 55",
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.